Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Backgrounds/Aims: The trends in mortality of hepatocellular carcinoma (HCC) and biliary tract cancers stratified by sex and race/ethnicity in the US continue to evolve. We estimated the sex- and race/ethnicity-based trends in HCC and biliary tract cancers-related mortality in US adults with a focus on disease burden. Methods: We performed a population-based analysis using the US national mortality records from 2018 to 2023. We identified HCC and biliary tract cancer using appropriate ICD-10 codes. Temporal trends in mortality were calculated by joinpoint analysis with annual percentage change (APC). Results: Annual age-standardized mortality from HCC decreased steadily with an APC of –1.4% (95% confidence interval [CI] –2.0% to –0.7%). While there was a linear increase in intrahepatic cholangiocarcinoma-related mortality (APC 3.1%; 95% CI 1.2–4.9%) and ampulla of Vater cancer-related mortality (APC 4.1%; 95% CI 0.5–7.9%), gallbladder cancer-related mortality decreased (APC –1.9%; 95% CI –3.8% to –0.0%). Decreasing trends in mortality from HCC were noted in males, not females. HCC-related mortality decreased more steeply in racial and ethnic minority individuals compared with non-Hispanic White individuals. Racial and ethnic differences in trends in mortality for biliary tract cancers depended on the malignancy’s anatomical site. Conclusions: While the annual mortality for HCC and gallbladder cancer demonstrated declining trends, ICC- and AVC-related mortality continued to increase from 2018 to 2023. Although racial and ethnic minority individuals in the US experienced disproportionately higher HCC and biliary tract cancer, recent declines in HCC may be primarily due to declines among racial and ethnic minority individuals and males.
Abstract
Backgrounds/Aims: The trends in mortality of hepatocellular carcinoma (HCC) and biliary tract cancers stratified by sex and race/ethnicity in the US continue to evolve. We estimated the sex- and race/ethnicity-based trends in HCC and biliary tract cancers-related mortality in US adults with a focus on disease burden. Methods: We performed a population-based analysis using the US national mortality records from 2018 to 2023. We identified HCC and biliary tract cancer using appropriate ICD-10 codes. Temporal trends in mortality were calculated by joinpoint analysis with annual percentage change (APC). Results: Annual age-standardized mortality from HCC decreased steadily with an APC of –1.4% (95% confidence interval [CI] –2.0% to –0.7%). While there was a linear increase in intrahepatic cholangiocarcinoma-related mortality (APC 3.1%; 95% CI 1.2–4.9%) and ampulla of Vater cancer-related mortality (APC 4.1%; 95% CI 0.5–7.9%), gallbladder cancer-related mortality decreased (APC –1.9%; 95% CI –3.8% to –0.0%). Decreasing trends in mortality from HCC were noted in males, not females. HCC-related mortality decreased more steeply in racial and ethnic minority individuals compared with non-Hispanic White individuals. Racial and ethnic differences in trends in mortality for biliary tract cancers depended on the malignancy’s anatomical site. Conclusions: While the annual mortality for HCC and gallbladder cancer demonstrated declining trends, ICC- and AVC-related mortality continued to increase from 2018 to 2023. Although racial and ethnic minority individuals in the US experienced disproportionately higher HCC and biliary tract cancer, recent declines in HCC may be primarily due to declines among racial and ethnic minority individuals and males.
참고문헌 (30)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Siegel RL, "Cancer statistics, 2024", CA Cancer J Clin, 74, pp.12~49 (2024)
- Kim D, "Decline in annual mortality of hepatitis C virus-related hepatocellular carcinoma in the United States, from 2009 to 2018", Gastroenterology, 159, pp.1558~1560 (2020)
- Van Dyke AL, "Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013", Cancer, 125, pp.1489~1498 (2019)
- Hemming AW, "Biliary tract and primary liver tumors: Who, what, and why?", Surg Oncol Clin N Am, 28, pp.519~538 (2019)
- Kim D, "Trends in the mortality of biliary tract cancers based on their anatomical site in the United States from 2009 to 2018", Am J Gastroenterol, 116, pp.1053~1062 (2021)
- Kim D, "Changing trends in etiology-based and ethnicitybased annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States", Hepatology, 69, pp.1064~1074 (2019)
- Kuderer NM, "Clinical impact of COVID-19 on patients with cancer(CCC19) : a cohort study", Lancet, 395, pp.1907~1918 (2020)
- Maddock J, "Inequalities in healthcare disruptions during the COVID-19 pandemic : evidence from 12 UK populationbased longitudinal studies", BMJ Open, 12, pp.e064981~ (2022)
- Shiels MS, "Racial and ethnic disparities in excess deaths during the COVID-19 pandemic, March to December 2020", Ann Intern Med, 174, pp.1693~1699 (2021)
- Ahmad FB, "Provisional mortality data-United States, 2020", MMWR Morb Mortal Wkly Rep, 70, pp.519~522 (2021)
- Xu J, "Deaths: Final data for 2019", Natl Vital Stat Rep (2021)[DOI]
- Kim D, "Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017", Gastroenterology, 157, pp.1055~1066 (2019)
- Yang Q, "Vital signs : Recent trends in stroke death rates-United States, 2000-2015", MMWR Morb Mortal Wkly Rep, 66, pp.933~939 (2017)
- Flanagin A, "Updated guidance on the reporting of race and ethnicity in medical and science journals", JAMA, 326, pp.621~627 (2021)
- Kim HJ, "Permutation tests for joinpoint regression with applications to cancer rates", Stat Med, 19, pp.335~351 (2000)
- Clegg LX, "Estimating average annual per cent change in trend analysis", Stat Med, 28, pp.3670~3682 (2009)
- Alvarez CS, "Racial", ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018, 2022, pp.76, 589~598
- O’Brien TR, "Decreasing incidence of hepatocellular carcinoma among most racial groups : SEER-22, 2000-2019", Cancer Med, 12, pp.19960~19967 (2023)
- Calvaruso V, "Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents", Gastroenterology, 155, pp.411~421 (2018)
- Romano A, "Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs : A prospective population study", J Hepatol, 69, pp.345~352 (2018)
- Alvarez CS, "Trends in hepatocellular carcinoma stage by racial", ethnic group in the United States, 1992-2019, 2023, pp.5, 100868~
- Phipps M, "Gender matters : Characteristics of hepatocellular carcinoma in women from a large, multicenter study in the United States", Am J Gastroenterol, 115, pp.1486~1495 (2020)
- Ilyas SI, "Cholangiocarcinoma-evolving concepts and therapeutic strategies", Nat Rev Clin Oncol, 15, pp.95~111 (2018)
- Antwi SO, "Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995-2014", Ann Hepatol, 17, pp.604~614 (2018)
- Nassour I, "Racial and ethnic disparities in a national cohort of ampullary cancer patients", J Surg Oncol, 117, pp.220~227 (2018)
- Henley SJ, "Gallbladder cancer incidence and mortality, United States 1999-2011", Cancer Epidemiol Biomarkers Prev, 24, pp.1319~1326 (2015)
- Alexander S, "Gallbladder cancer, a vanishing disease?", Cancer Causes Control, 23, pp.1705~1709 (2012)
- Ilyas Khan A, "Impact of the COVID-19 pandemic on the management of gallbladder, biliary tract, and pancreatic diseases", Cureus, 15, pp.e43473~ (2023)
- Khan SA, "Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma", J Hepatol, 71, pp.1261~1262 (2019)